CINNATROPIN 30 IU (10 mg) is a recombinant Human Growth Hormone [somatropin rDNA origin] delivered via a precision-engineered injectable pen device. The pen system incorporates a lyophilized powder and sterile injection solution in separate compartments, with an integrated mixing mechanism activated prior to administration. Cinnatropin is available for clinical and research use in Thailand and internationally.
 
✔ Key Research Insights
Studied for its role in stimulating IGF-1 production in the liver, with downstream effects on cellular growth and regeneration documented in clinical research
Investigated for its influence on immune system function in research subjects across documented clinical observations
Examined for its effects on metabolic processes, including fat oxidation and lean mass parameters in subject populations
Researched for its established clinical indications in growth hormone deficiency in pediatric and adult populations, including conditions such as Turner syndrome, Noonan syndrome, Prader-Willi syndrome, and short stature associated with absent catch-up growth
Documented for its role in managing muscle wasting associated with HIV/AIDS and short bowel syndrome in clinical literature
Researched for its effects on tissue maintenance and repair, including musculoskeletal and organ-level regeneration, in documented subject populations
Studied for its influence on post-injury recovery and metabolic rate in clinical research settings
 
📦 Product Specifications
Product: CINNATROPIN
Molecule: Somatropin (rDNA origin) — 191 amino acid sequence
Concentration: 30 IU / 10 mg
Form: Lyophilized powder with sterile solvent, pre-filled injectable pen
Administration: Subcutaneous injection
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
Somatropin is a recombinant DNA-derived human growth hormone consisting of a 191-amino acid chain identical in structure to endogenous pituitary-derived HGH. Due to its peptide nature, somatropin is not orally bioavailable, as gastric acid degrades the molecule prior to systemic absorption; subcutaneous or intramuscular injection is therefore the required route of administration in all documented clinical protocols. Following injection in research subjects, somatropin acts on hepatic receptors to stimulate the production of insulin-like growth factor 1 (IGF-1), the primary downstream mediator of growth hormone activity throughout the body. Documented effects in clinical literature include influences on bone and muscle development, tissue repair and regeneration, metabolic regulation, and immune function. The Cinnatropin pen device facilitates accurate dosing through its integrated dual-compartment mixing system, maintaining the stability of the lyophilized compound until the point of administration.
 
⭐ Product Overview
Precision-engineered injectable pen with integrated lyophilized powder and sterile solvent compartments for consistent pre-administration mixing
Recombinant DNA-derived somatropin formulation with a 191-amino acid sequence identical to endogenous human growth hormone
Clinically established compound with documented indications across pediatric and adult growth hormone deficiency, wasting conditions, and metabolic disorders
Pharmaceutical-grade manufacturing standards ensuring compound purity, potency, and stability